Abbott is the name behind many well-known products.

ABT, is repositioning its business after ongoing challenges in its Nutrition segment. The company is advancing a major acquisition of Exact Sciences to expand into oncology diagnostics. Management is ...

Abbott Laboratories reported strong Q4 2023 earnings, with year-over-year growth in EPS and revenue. The company's 2024 guidance projects further growth and improved ...

The S&P 500 has performed well in 2023, but healthcare stocks have lagged behind. Abbott Laboratories continues to lap difficult comparable quarterly earnings reports, but the core business has been ...

Abbott Laboratories (NYSE:ABT) received an FDA warning letter focused on the accuracy and testing of its FreeStyle Libre ...

Abbott Laboratories’ financial results were negatively impacted by a sharp drop in COVID-19 test sales in Q1. The company’s market-beating dividend is well covered. The stock’s valuation appears to be ...

On Wednesday, Abbott Laboratories (NYSE:ABT) reported fourth-quarter sales of $10.97 billion, up 7.2% year over year, missing the consensus of $11.01 billion. Organic sales growth for the underlying ...

Abbott Laboratories (NYSE:ABT) will release its quarterly earnings report on Wednesday, 2024-10-16. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Abbott ...